Novo Nordisk is suing Eli Lilly, accusing the company of using outdated clinical data in its advertising for weight-loss and diabetes drugs to mislead consumers. The lawsuit alleges Lilly's ads compare high doses of its drugs to lower doses of Novo's, omitting crucial context about newer, more effective versions of Novo's medications.
The Lawsuit and Allegations
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging that Lilly's advertising campaigns for its weight-loss and diabetes drugs mislead consumers by using outdated clinical data. The Danish pharmaceutical company claims Lilly's ads compare the highest doses of its own drugs to lower doses of Novo Nordisk's medications, omitting critical context about newer, more effective versions of Novo's products.
The lawsuit, filed in U.S. District Court in New Jersey, seeks a permanent injunction to halt Lilly's ads and requires the company to issue corrective advertising. Novo Nordisk also seeks financial damages. The dispute centers on ads that claim Lilly's drugs, such as Zepbound and Mounjaro, are more effective than Novo's Wegovy and Ozempic, based on trials that do not account for Novo's recently approved higher-dose versions.
Eli Lilly's Defense
Eli Lilly has defended its advertising, stating that it is 'truthful, transparent, and grounded in the most direct scientific evidence available.' The company has vowed to vigorously defend against the lawsuit. Novo Nordisk argues that Lilly's ads create a misleading impression of superiority, despite newer data showing comparable results between the drugs.
Market Competition and Drug Landscape
The legal battle comes as both companies compete fiercely in the growing market for GLP-1 weight-loss drugs. Novo Nordisk was the first to market with Wegovy, but Lilly's Zepbound has seen surging sales, reaching nearly $4.2 billion in the first quarter of 2026. Analysts expect the weight-loss drug sector to generate about $100 billion annually.
Novo Nordisk's general counsel, John Kuckelman, emphasized the importance of accurate information for patients. 'Healthcare companies have a responsibility to keep their public claims accurate and current,' he said. The lawsuit follows a cease-and-desist letter sent by Novo Nordisk in April, which Lilly did not comply with.